| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Loss before income taxes | -11,345 | -9,471 | ||
| Income tax benefit (expense) | 0 | 0 | ||
| Net loss | -11,345 | -9,471 | ||
| Less cumulative series d preferred dividends | 0 | 0 | ||
| Loss attributable to common stockholders | -11,345 | -9,471 | ||
| Foreign currency translation gain | 215 | -108 | ||
| Comprehensive loss | -11,130 | -9,579 | ||
| Basic (in shares) | 11,064,282 | 11,052,741 | ||
| Diluted (in shares) | 11,064,282 | 11,052,741 | ||
| Us-gaap_earningspersharebasic | -1.03 | -0.86 | ||
| Us-gaap_earningspersharediluted | -1.03 | -0.86 | ||
PALVELLA THERAPEUTICS, INC. (PVLA)
PALVELLA THERAPEUTICS, INC. (PVLA)